TNF and ankylosing spondylitis: IFX, a recombinant humanized monoclonal antibody against TNF-α, is now approved for use in several immune-mediated disorders, including psoriasis, RA, IBD, ankylosing spondylitis, and IVIG resistant KD (74–77).